KemPharm, Inc. (KMPH) News

KemPharm, Inc. (KMPH): $5.97

-0.47 (-7.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KMPH to Watchlist
Sign Up

Industry: Biotech


Ranked

of 403

in industry

Filter KMPH News Items

KMPH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest KMPH News From Around the Web

Below are the latest news stories about Kempharm Inc that investors may wish to consider to help them evaluate KMPH as an investment opportunity.

KemPharm selects KP1077 for idiopathic hypersomnia as lead SDX candidate

KemPharm (KMPH) has added ~3.9% in the post-market after announcing the selection of KP1077 for idiopathic hypersomnia ((IH)) as its lead serdexmethylphenidate ((SDX)) candidate in

Seeking Alpha | January 19, 2022

KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy

KemPharm to Advance KP1077 for Idiopathic Hypersomnia as Lead SDX Product Candidate Strong Balance Sheet with Cash and Cash Equivalents of $127.8M as of December 31, 2021; Available Cash and Revenues Extend Cash Runway through 2025 and Beyond AZSTARYS® National Launch Accelerating, Full Sales Team in Place by end of January 2022 Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, January 19, 2022, at 4:30 p.m. ET CELEBRATION, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -

Yahoo | January 19, 2022

KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, January 19, 2022 at 4:30 p.m. ET CELEBRATION, Fla., Jan. 12, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, January 19, 2022, at 4:30 p.m. ET, to discuss the Company’s strategy for advancing and expandi

Yahoo | January 12, 2022

KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference

Data highlight key pharmacokinetic properties of serdexmethylphenidate that are instrumental to its consistent and smooth release of d-MPH CELEBRATION, Fla., Jan. 11, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that research involving serdexmethylphenidate (SDX), the company’s proprietary prodrug of d-methylphenidate (d-MPH), will be featured in two poster presentati

Yahoo | January 11, 2022

KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022”

CELEBRATION, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today the company is participating in BIO Partnering @ JPM, which is being held virtually alongside the J.P. Morgan 40th Annual Healthcare Conference 2022. Details of the events are as follows: Event: BIO Partnering @ JPMDate: January 10-14, 2022Registration: https://www.bio.org/events/bio-partnering-j

Yahoo | January 6, 2022

Implied Volatility Surging for KemPharm (KMPH) Stock Options

Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.

Yahoo | December 28, 2021

Insider Trading At KemPharm Inc. (NASDAQ: KMPH): What Did We Note?

KemPharm Inc. (NASDAQ:KMPH) traded at $8.31 at close of the session on Monday, 12/20/21, made an upward move of 6.81% on its previous days price. Looking at the stock we see that its previous close was $7.78 and the beta (5Y monthly) reads 3.21 with the days price range being $7.66 $8.91. In terms Insider Trading At KemPharm Inc. (NASDAQ: KMPH): What Did We Note? Read More »

Stocks Register | December 21, 2021

KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program

CELEBRATION, Fla., Dec. 20, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today its Board of Directors has authorized a program to repurchase up to $50 million of the Company’s outstanding stock. The share repurchase authorization is effective immediately and valid through December 31, 2023. This program is equivalent to approximately 18 percent of KemPharm’s current market

Yahoo | December 20, 2021

Kempharm added to Nasdaq Biotechnology index

No summary available.

Seeking Alpha | December 14, 2021

KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of Higher-Dose SDX

Data reveal serdexmethylphenidate (SDX) delivered at doses higher than those studied with AZSTARYS ® is well-tolerated, yields dose-proportional d-MPH exposure, and produces targeted biological effects

Intrado Digital Media | December 14, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5028 seconds.